Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-03-31

FDA Approved: SYMTUZA — Supplemental Application (Janssen Products LP)

View source ↗

Summary

The FDA approved a supplemental application for SYMTUZA (darunavir, cobicistat, emtricitabine, and tenofovir alafenamide), a fixed-dose HIV-1 therapy from Janss…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

SUPPL AP for SYMTUZA (DARUNAVIR, COBICISTAT, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE)